A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis
Skin whitening treatment plans have emerged as an increasing number of famous individuals trying to attain a brighter, more even complexion
In November 2025, the drugmaker Novo Nordisk announced that two large and much anticipated studies failed to find any benefit for its GLP-1 medicine in patients with early stage Alzheimers disease
Sample name: the product of the invention (batch number P-110201, specification 0.6g) Preparing a compatible injection: 0.9% sodium chloride injection, manufactured by Chongqing Di kang Yangtze pharmaceutical Co., Ltd 5% glucose injection, manufactured by Tai Ji southwest pharmaceutical industries, Ltd 10% glucose injection, manufactured by Tai Ji southwest pharmaceutical industries, Ltd Water for injection, made by Investigation time: 0h, 2h, 4h and 6h And (4) investigation indexes are as follows: the results of the product of the invention in four injections at ambient temperature conditions (dilution to measured concentration, measured only at 0h, 2h, 4h, 6 h) for clarity, pH, visible foreign matter, insoluble particles, related substances (area normalization) are shown in tables 7-8